诺维本联合希罗达治疗晚期转移性乳腺癌疗效观察  

Navelbine Combined With Capecitabine in the Treatment of Relapsed and Metastatic Breast Cancer

作　　者：赵怡[1] 章骏[1] 杨志刚[1] 曹伟[1] 周咸亮[1] 

机构地区：[1]上海市杨浦区市东医院肿瘤外科,200438

出　　处：《实用癌症杂志》2010年第6期612-615,共4页The Practical Journal of Cancer

摘　　要：目的探讨诺维本联合希罗达治疗复发转移乳腺癌的近期疗效和不良反应。方法 32例复发转移性乳腺癌患者,诺维本25mg/m2静脉滴注,第1,8天;希罗达2250mg/(m2·d),分早晚2次餐后30min口服,连用2周,休息1周为1个周期。每例患者至少进行2个周期的治疗。结果 32例可评价疗效和不良反应的患者中,完全缓解(CR)5例,部分缓解(PR)12例,病情稳定(SD)11例,病情进展(PD)4例,总有效率53.12%,临床获益患者(CR+PR+SD)28例(87.5%)。常见不良反应为手足综合征、皮肤色素沉着、恶心、呕吐、厌食、疲劳,少数患者出现口腔炎、头晕、腹泻和胸闷。36.4%的患者有轻～中度贫血和白细胞下降,1例Ⅳ度骨髓抑制,个别患者胆红素和谷丙转氨酶轻度升高。结论诺维本联合希罗达是治疗复发转移乳腺癌患者的有效疗法,尤其是对紫杉类治疗失败的患者仍有效。治疗过程中患者耐受性好,不良反应轻。Objective To evaluate the response rate and adverse reactions of navelbine combined with capecitabine in the treatment of relapsed and metastatic breast cancer.Methods Thirty-two breast cancer patients with recurrent or metastatic measurable foci were treated by Navelbine and capecitabine.Navelbine was given at a dose of 25 mg/m2 on day 1 and day 8,and Capecitabine was given at a dose of 2250 mg/m2 /d,twice daily for two weeks followed by one week of rest as one cycle,at least two cycles were given to each patient.Results Of the 32 patients,5 achieved complete response,12 achieved partial response,with a total response rate of 53.1%.There were 11 patients with stable disease,with a clinical benefit response（CR ＋ PR ＋ SD） of 87.5 %.The common adverse reactions were hand-foot syndrome,skin pigmentation,nausea,vomiting,anorexia and fatigue.Mild-moderate anemia and leukopenia were observed in 36.4% of patients.One patient developed degree Ⅳ myelosuppression.Total bilirubin and alanine transaminase（ALAT） mild elevation occurred in a few patients.Conclusion Navelbine combined with capecitabine is an effective rigmens in the treatment of patients with relapsed and metastatic breast cancer,especially for those who have failed in chemotherapy with anthracycline.The rigmens is well tolerated but has mild adverse reactions.

关 键 词：乳腺癌 诺维本 希罗达 化疗 肿瘤转移 

分 类 号：R737.9[医药卫生—肿瘤]